Halozyme Therap

HALO

----

Current ValuationThe current P/E ratio is 35.68, above the reasonable range, cheaper than 0% of the time in the past 3 years, and the industry ranks 49/606, the industry Median -2.02.

35.68xP/E

Stock price$130.03Earnings per share$3.64

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
VRTXUSVertex Pharma	30.48x	10.01%	$134.26B
GMABUSGenmab A/S	44.71x	26.47%	$35.23B
ALNYUSAlnylam Pharma	40.14x	184.62%	$31.10B
HALOUSHalozyme Therap	35.68x	185.16%	$14.76B
KRYSUSKrystal Biotech	39.40x	6.30%	$9.51B
VCYTUSVeracyte	35.33x	35.02%	$4.04B
CDNAUSCaredex	33.61x	618.00%	$3.73B
PHARUSPharming Group NV	35.89x	562.50%	$867.74M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.